Login / Signup

Low baseline plasma PCSK9 level is associated with good clinical outcomes of immune checkpoint inhibitors in advanced non-small cell lung cancer.

Mengqing XieXin YuXiangling ChuHuikang XieJuan ZhouJing ZhaoChunxia Su
Published in: Thoracic cancer (2021)
Low baseline plasma PCSK9 level may predict good outcomes in patients with advanced NSCLC treated with ICIs.
Keyphrases
  • advanced non small cell lung cancer
  • epidermal growth factor receptor
  • small cell lung cancer
  • low density lipoprotein
  • tyrosine kinase
  • newly diagnosed